News Related to Moderately to Severely Active Crohns Disease

Related coverage linked through entity extraction aliases.

TREMFYA® Shows Sustained Remission in Ulcerative Colitis Through Week 140

Feb 21, 2026

Long-term data from the QUASAR extension study show TREMFYA® maintained clinical remission in over 80% of ulcerative colitis patients at Week 140, with more than half achieving endoscopic remission and no new safety concerns observed.

Omvoh Maintains 91% Steroid-Free Remission in Crohn's Disease Through Three Years

Feb 20, 2026

Eli Lilly's Omvoh demonstrated durable efficacy in Crohn's disease, with over 90% of patients maintaining steroid-free clinical remission through three years of monthly treatment in the Phase III VIVID-2 extension study.